Today: 20 March 2026
Subscribe
Browse Category

ASX:MSB 3 October 2025 - 6 March 2026

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast shares rose 3% in early U.S. trading Friday after the company reported first-half revenue of $51.3 million, up from $3.2 million a year earlier, driven by Ryoncil sales. The company set a fiscal 2026 net revenue target of $110–$120 million for Ryoncil and said 49 transplant centers have been onboarded. Cash stood at $130 million as of Dec. 31. An adult trial for Ryoncil is expected to begin after ethics approval in March.
6 March 2026
·
Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

The S&P/ASX 200 closed up 0.29% at 8,720.8, led by gains in tech and healthcare, while miners fell. BlueScope rejected a A$13.2 billion takeover bid from SGH and Steel Dynamics. Ansell shares dropped 6.2% as CEO Neil Salmon announced his retirement, with Nathalie Ahlström set to take over in February. The Australian dollar slipped to about 67 U.S. cents.
8 January 2026
·········
Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

The S&P/ASX 200 rose 0.81% to 8,606.5 Wednesday, shrugging off a jump in annual inflation to 3.8%. Temple & Webster plunged 32% after weak revenue growth, while National Storage REIT surged nearly 20% on a $4 billion takeover bid. The Australian dollar climbed to US$0.6505. Miners and healthcare stocks led gains.
26 November 2025
·········
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast shares closed at $17.02 on Oct. 2, up 4.6% after the FDA-approved Ryoncil won permanent CMS reimbursement via a new J-code. The company confirmed its cell therapies are made from U.S. donors and not subject to tariffs. Wall Street consensus is “Buy” with a $24 average price target. Hedge funds have increased stakes, but overall institutional ownership remains low.
3 October 2025
··

Stock Market Today

  • Asia Markets Fall as Iran Conflict Drives Global Risk-Off; Energy Prices Surge
    March 19, 2026, 9:39 PM EDT. Asian markets edged lower following Wall Street losses amid escalating tensions in the Middle East sparked by Iran's attacks on key energy infrastructure. Tehran's strike on Qatar's largest gas plant slashed LNG export capacity by 17% for years, pushing energy prices higher. U.S. natural gas and Brent crude rose over 1%, with gasoline nearing a four-year peak, underscoring supply concerns. Metals saw volatile moves, gold and silver dropping before recovering. Despite market jitters, U.S. President Trump and Israeli Prime Minister Netanyahu signaled restraint, dampening fears of prolonged conflict. A coalition of U.S.-aligned nations pledged to protect key shipping routes, including the Strait of Hormuz. Asian markets showed mixed reactions, with South Korea's Kospi rising, while Australia's S&P/ASX 200 and Hong Kong futures declined. Wall Street indexes closed down modestly after the Federal Reserve held interest rates steady.
Go toTop